Literature DB >> 18650452

Longitudinal analysis of heart and liver iron in thalassemia major.

Leila J Noetzli1, Susan M Carson, Anne S Nord, Thomas D Coates, John C Wood.   

Abstract

High hepatic iron concentration (HIC) is associated with cardiac iron overload. However, simultaneous measurements of heart and liver iron often demonstrate no significant linear association. We postulated that slower rates of cardiac iron accumulation and clearance could reconcile these differences. To test this hypothesis, we examined the longitudinal evolution of cardiac and liver iron in 38 thalassemia major patients, using previously validated magnetic resonance imaging (MRI) techniques. On cross-sectional evaluation, cardiac iron was uncorrelated with liver iron, similar to previous studies. However, relative changes in heart and liver iron were compared with one another using a metric representing the temporal delay between them. Cardiac iron significantly lagged liver iron changes in almost half of the patients, implying a functional but delayed association. The degree of time lag correlated with initial HIC (r = 0.47, P < .003) and initial cardiac R2* (r = 0.57, P < .001), but not with patient age. Thus, longitudinal analysis confirms a lag in the loading and unloading of cardiac iron with respect to liver iron, and partially explains the weak cross-sectional association between these parameters. These data reconcile several prior studies and provide both mechanical and clinical insight into cardiac iron accumulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650452      PMCID: PMC2556627          DOI: 10.1182/blood-2008-04-148767

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease.

Authors:  John C Wood; J Michael Tyszka; Susan Carson; Marvin D Nelson; Thomas D Coates
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

2.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool.

Authors:  Peter D Jensen; Finn T Jensen; Thorkil Christensen; Hans Eiskjaer; Ulrik Baandrup; Johan L Nielsen
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

3.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.

Authors:  Lisa J Anderson; Beatrix Wonke; Emma Prescott; Sally Holden; J Malcolm Walker; Dudley J Pennell
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

4.  Deferoxamine-induced iron mobilization and redistribution of myocardial iron in cultured rat heart cells: studies of the chelatable iron pool by electron microscopy and Mössbauer spectroscopy.

Authors:  H Shiloh; T C Iancu; E R Bauminger; G Link; A Pinson; C Hershko
Journal:  J Lab Clin Med       Date:  1992-04

5.  Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.

Authors:  Lisa J Anderson; Mark A Westwood; Sally Holden; Bernard Davis; Emma Prescott; Beatrix Wonke; John B Porter; J Malcolm Walker; Dudley J Pennell
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

6.  L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy.

Authors:  Gavin Y Oudit; Hui Sun; Maria G Trivieri; Sheryl E Koch; Fayez Dawood; Cameron Ackerley; Mehrdad Yazdanpanah; Greg J Wilson; Arnold Schwartz; Peter P Liu; Peter H Backx
Journal:  Nat Med       Date:  2003-08-24       Impact factor: 53.440

7.  Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells.

Authors:  J G Parkes; R A Hussain; N F Olivieri; D M Templeton
Journal:  J Lab Clin Med       Date:  1993-07

8.  Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major.

Authors:  Bernard A Davis; Caoimhe O'Sullivan; Peter H Jarritt; John B Porter
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

9.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.

Authors:  Caterina Borgna-Pignatti; Simone Rugolotto; Piero De Stefano; Huaqing Zhao; Maria Domenica Cappellini; Giovanni Carlo Del Vecchio; Maria Antonietta Romeo; Gian Luca Forni; Maria Rita Gamberini; Roberta Ghilardi; Antonio Piga; Avital Cnaan
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

10.  Onset of cardiac iron loading in pediatric patients with thalassemia major.

Authors:  John C Wood; Raffaella Origa; Annalisa Agus; Gildo Matta; Thomas D Coates; Renzo Galanello
Journal:  Haematologica       Date:  2008-04-15       Impact factor: 9.941

View more
  68 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.

Authors:  George B McDonald
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

3.  Rapid monitoring of iron-chelating therapy in thalassemia major by a new cardiovascular MR measure: the reduced transverse relaxation rate.

Authors:  Daniel Kim; Jens H Jensen; Ed X Wu; Li Feng; Wing-Yan Au; Jerry S Cheung; Shau-Yin Ha; Sujit S Sheth; Gary M Brittenham
Journal:  NMR Biomed       Date:  2010-12-28       Impact factor: 4.044

4.  Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Authors:  Janet L Kwiatkowski; Hae-Young Kim; Alexis A Thompson; Charles T Quinn; Brigitta U Mueller; Isaac Odame; Patricia J Giardina; Elliott P Vichinsky; Jeanne M Boudreaux; Alan R Cohen; John B Porter; Thomas Coates; Nancy F Olivieri; Ellis J Neufeld
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

5.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Authors:  Russell E Ware; Ronald W Helms
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

6.  MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients.

Authors:  Diana X Nichols-Vinueza; Matthew T White; Andrew J Powell; Puja Banka; Ellis J Neufeld
Journal:  Am J Hematol       Date:  2014-04-10       Impact factor: 10.047

7.  Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.

Authors:  Yesim Aydinok; Antonis Kattamis; M Domenica Cappellini; Amal El-Beshlawy; Raffaella Origa; Mohsen Elalfy; Yurdanur Kilinç; Silverio Perrotta; Zeynep Karakas; Vip Viprakasit; Dany Habr; Niculae Constantinovici; Junwu Shen; John B Porter
Journal:  Blood       Date:  2015-05-01       Impact factor: 22.113

8.  Pulmonary function in thalassaemia major and its correlation with body iron stores.

Authors:  Eugene Y Sohn; Leila J Noetzli; Aakanksha Gera; Roberta Kato; Thomas D Coates; Paul Harmatz; Thomas G Keens; John C Wood
Journal:  Br J Haematol       Date:  2011-08-02       Impact factor: 6.998

Review 9.  Estimating tissue iron burden: current status and future prospects.

Authors:  John C Wood
Journal:  Br J Haematol       Date:  2015-03-12       Impact factor: 6.998

10.  Pregnancy Outcomes in Women with Homozygous Beta Thalassaemia: A single-centre experience from Oman.

Authors:  Nihal Al-Riyami; Maha Al-Khaduri; Shahina Daar
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.